婴儿痉挛症治疗市场－全球产业规模、份额、趋势、机会和预测，依治疗类别、药物类型（氨己烯酸、促肾上腺皮质激素、其他）、剂量、地区和竞争格局划分，2020-2030年预测

2024年全球婴儿痉挛症治疗药物市场规模为33.2亿美元，预计到2030年将以4.04%的复合年增长率增长至42.1亿美元。婴儿痉挛症治疗药物包括专门用于治疗婴儿痉挛症的药物。婴儿痉挛症是一种严重的罕见癫痫性脑病，其特征是婴儿出现短暂、突发的肌肉收缩，且常呈簇状发作。推动市场成长的主要因素包括全球对该疾病认识的提高、诊断方法的进步使得早期检测成为可能，以及预防与该疾病相关的严重神经发育倒退的迫切医疗需求。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球婴儿痉挛症治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依治疗类别（抗惊厥药、皮质类固醇、其他）
  • 依药物类型（氨己烯酸、促肾上腺皮质激素、其他（III期））
  • 按剂量（固体、液体）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美婴儿痉挛症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲婴儿痉挛症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区婴儿痉挛症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲婴儿痉挛症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲婴儿痉挛症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球婴儿痉挛症治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Anavex Life Sciences Corp.
• H. Lundbeck A/S
• Catalyst Pharmaceuticals, Inc.
• Jazz Pharmaceuticals, Inc.
• Travere Therapeutics, Inc.
• Valerion Therapeutics LLC
• ORPHELIA Pharma
• Novartis AG
• Sanofi SA
• Pfizer Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Infantile Spasm Therapeutics Market , valued at USD 3.32 Billion in 2024, is projected to experience a CAGR of 4.04% to reach USD 4.21 Billion by 2030. Infantile spasm therapeutics comprise pharmaceutical agents specifically developed to treat infantile spasms, a severe and rare epileptic encephalopathy characterized by brief, abrupt muscle contractions often occurring in clusters in infants. Main market growth drivers include increasing global disease awareness, advancements in diagnostic methodologies enabling earlier detection, and the critical unmet medical need to prevent severe neurodevelopmental regression associated with the condition.

Key Market Drivers

The increasing prevalence of infantile spasms substantially drives the therapeutics market by expanding the treatable patient population. Improved diagnostic techniques and heightened awareness among medical professionals and caregivers facilitate earlier detection of these severe epileptic encephalopathies. Prompt diagnosis is critical for mitigating long-term neurodevelopmental consequences. According to data presented at the American Epilepsy Society in December 2024, from a cohort study, incidental diagnosis of Infantile Epileptic Spasms Syndrome (IESS) was observed in 29% of patients. This demonstrates how proactive screening brings more cases into the treatment pathway, directly fueling market demand.

Key Market Challenges

A significant challenge impeding the expansion of the Global Infantile Spasm Therapeutics Market stems from the high cost associated with existing first-line treatments, such as adrenocorticotropic hormone, coupled with often complex reimbursement processes. This financial burden critically limits patient access to timely and effective therapies, particularly in regions with developing healthcare infrastructures. The inability of patients to afford or readily obtain these essential medications directly translates into under-treatment or delayed intervention.

Key Market Trends

The Global Infantile Spasm Therapeutics Market is significantly shaped by the emergence of precision and genetically-targeted therapies. This trend represents a fundamental shift towards developing treatments that address the specific underlying genetic causes of infantile spasms, moving beyond broad-spectrum approaches. This individualized therapeutic strategy holds the promise of improved efficacy and reduced side effects for distinct patient populations. According to the American Epilepsy Society (AES), a study presented at their 2024 annual meeting highlighted that studies including non-European participants, representing only 16% of 68 genome-wide association studies, identified 58% of significant Single Nucleotide Polymorphisms linked to epilepsy. This demonstrates the impact of genetic research in uncovering crucial insights for targeted interventions.

Key Market Players

• Anavex Life Sciences Corp.
• H. Lundbeck A/S
• Catalyst Pharmaceuticals, Inc.
• Jazz Pharmaceuticals, Inc.
• Travere Therapeutics, Inc.
• Valerion Therapeutics LLC
• ORPHELIA Pharma
• Novartis AG
• Sanofi SA
• Pfizer Inc.

Report Scope:

In this report, the Global Infantile Spasm Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infantile Spasm Therapeutics Market , By Therapeutic Class:

• Anticonvulsants
• Corticosteroids
• Others

Infantile Spasm Therapeutics Market , By Drug Type:

• Vigabatrin
• Adrenocorticotropic Hormone
• Others (Phase III)

Infantile Spasm Therapeutics Market , By Dosage:

• Solid
• Liquid

Infantile Spasm Therapeutics Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Infantile Spasm Therapeutics Market .

Available Customizations:

Global Infantile Spasm Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infantile Spasm Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutic Class (Anticonvulsants, Corticosteroids, Others)
  • 5.2.2. By Drug Type (Vigabatrin, Adrenocorticotropic Hormone, Others (Phase III))
  • 5.2.3. By Dosage (Solid, Liquid)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Infantile Spasm Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutic Class
  • 6.2.2. By Drug Type
  • 6.2.3. By Dosage
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Infantile Spasm Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutic Class
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Dosage
  • 6.3.2. Canada Infantile Spasm Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutic Class
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Dosage
  • 6.3.3. Mexico Infantile Spasm Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutic Class
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Dosage

7. Europe Infantile Spasm Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutic Class
  • 7.2.2. By Drug Type
  • 7.2.3. By Dosage
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Infantile Spasm Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutic Class
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Dosage
  • 7.3.2. France Infantile Spasm Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutic Class
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Dosage
  • 7.3.3. United Kingdom Infantile Spasm Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutic Class
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Dosage
  • 7.3.4. Italy Infantile Spasm Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutic Class
      • 7.3.4.2.2. By Drug Type
      • 7.3.4.2.3. By Dosage
  • 7.3.5. Spain Infantile Spasm Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutic Class
      • 7.3.5.2.2. By Drug Type
      • 7.3.5.2.3. By Dosage

8. Asia Pacific Infantile Spasm Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutic Class
  • 8.2.2. By Drug Type
  • 8.2.3. By Dosage
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Infantile Spasm Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutic Class
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Dosage
  • 8.3.2. India Infantile Spasm Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutic Class
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Dosage
  • 8.3.3. Japan Infantile Spasm Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutic Class
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Dosage
  • 8.3.4. South Korea Infantile Spasm Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutic Class
      • 8.3.4.2.2. By Drug Type
      • 8.3.4.2.3. By Dosage
  • 8.3.5. Australia Infantile Spasm Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutic Class
      • 8.3.5.2.2. By Drug Type
      • 8.3.5.2.3. By Dosage

9. Middle East & Africa Infantile Spasm Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutic Class
  • 9.2.2. By Drug Type
  • 9.2.3. By Dosage
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Infantile Spasm Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutic Class
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Dosage
  • 9.3.2. UAE Infantile Spasm Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutic Class
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Dosage
  • 9.3.3. South Africa Infantile Spasm Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutic Class
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Dosage

10. South America Infantile Spasm Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutic Class
  • 10.2.2. By Drug Type
  • 10.2.3. By Dosage
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Infantile Spasm Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutic Class
      • 10.3.1.2.2. By Drug Type
      • 10.3.1.2.3. By Dosage
  • 10.3.2. Colombia Infantile Spasm Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutic Class
      • 10.3.2.2.2. By Drug Type
      • 10.3.2.2.3. By Dosage
  • 10.3.3. Argentina Infantile Spasm Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutic Class
      • 10.3.3.2.2. By Drug Type
      • 10.3.3.2.3. By Dosage

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Infantile Spasm Therapeutics Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Anavex Life Sciences Corp.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. H. Lundbeck A/S
• 15.3. Catalyst Pharmaceuticals, Inc.
• 15.4. Jazz Pharmaceuticals, Inc.
• 15.5. Travere Therapeutics, Inc.
• 15.6. Valerion Therapeutics LLC
• 15.7. ORPHELIA Pharma
• 15.8. Novartis AG
• 15.9. Sanofi SA
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer